ArticleFrontiers in cardiovascular medicine2025
Short-term outcomes of repair vs. replacement for rheumatic mitral valve disease.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The main types of surgery for rheumatic mitral valve disease are traditional percutaneous mitral balloon valvuloplasty (PMBV), mitral valve replacement (MVR) with removal of the original valve, and valve repair with preservation of the original valve. Some studies have shown that mitral valve repair (MVr) has certain advantages compared with replacement. Methods: The clinical data of 166 patients with rheumatic mitral valve lesions admitted to the Department of Cardiac Macrovascular Surgery of the Results: Hemodynamic evaluation of MVr: (1) left ventricular end-diastolic diameters (LVEDD), left atrial end-systolic diameters (LAESD), mitral E-wave velocity, left ventricular ejection fraction (LVEF), mitral valve orifice area (MVOA), mitral pressure halving time (PHT), and mean pressure gradient (MPG) at each time point after MVr were improved compared with preoperative values ( Conclusions: Mitral valve repair and mitral valve replacement are effective in the treatment of patients with rheumatic mitral valve disease, with greater hemodynamic improvement after mitral valve repair than replacement and with greater short-term clinical efficacy than valve replacement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.